WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406223
CAS#: 137530-61-1
Description: BE-16627B is a novel metalloproteinase (MP) inhibitor isolated from Streptomyces sp. BE16627B selectively inhibited MPs such as human stromelysin and 92 kD gelatinase. After the cells were cultured with BE16627B for 5 days, BE16627B inhibited MP activity in the primary culture supernatants from synovial cells in a dose-dependent fashion without showing apparent cytotoxicity or affecting the production and secretion of MPs. Its IC50 for active collagenolysis before activation by trypsin was 25 microM.
MedKoo Cat#: 406223
Name: BE-16627B
CAS#: 137530-61-1
Chemical Formula: C16H29N3O7
Exact Mass: 375.20055
Molecular Weight: 375.42
Elemental Analysis: C, 51.19; H, 7.79; N, 11.19; O, 29.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BE16627B; BE 16627B; BE-16627B; LN(Nhydroxy2isobutylsuccinamoyl)serylLvaline.
IUPAC/Chemical Name: (2S)-2-((2S)-3-hydroxy-2-(2-(2-(hydroxyamino)-2-oxoethyl)-4-methylpentanamido)propanamido)-3-methylbutanoic acid
SMILES Code: CC(C)[C@H](NC([C@@H](NC(C(CC(NO)=O)CC(C)C)=O)CO)=O)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 375.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Yoshida D, Watanabe K, Takahashi H, Sugisaki Y, Teramoto A. Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent. Brain Tumor Pathol. 2003;20(1):13-9. PubMed PMID: 14604227.
2: Sobue T, Hakeda Y, Kobayashi Y, Hayakawa H, Yamashita K, Aoki T, Kumegawa M, Noguchi T, Hayakawa T. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J Bone Miner Res. 2001 Dec;16(12):2205-14. PubMed PMID: 11760833.
3: Watanabe K, Yoshida D, Noha M, Teramoto A. Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B. J Neurooncol. 2001 Mar;52(1):1-9. PubMed PMID: 11451198.
4: Kiyama T, Onda M, Tokunaga A, Efron DT, Barbul A. Effect of matrix metalloproteinase inhibition on colonic anastomotic healing in rats. J Gastrointest Surg. 2001 May-Jun;5(3):303-11. PubMed PMID: 11360054.
5: Shibutani T, Yamashita K, Aoki T, Iwayama Y, Nishikawa T, Hayakawa T. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption. J Bone Miner Metab. 1999;17(4):245-51. PubMed PMID: 10575588.
6: Okuyama A, Akiyama T, Nakajima M. [CDK and MMP inhibitors]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1547-62. Review. Japanese. PubMed PMID: 9309154.
7: Tamaki K, Tanzawa K, Kurihara S, Oikawa T, Monma S, Shimada K, Sugimura Y. Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem Pharm Bull (Tokyo). 1995 Nov;43(11):1883-93. PubMed PMID: 8575029.
8: Okuyama A, Naito K, Morishima H, Suda H, Nishimura S, Tanaka N. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Ann N Y Acad Sci. 1994 Sep 6;732:408-10. PubMed PMID: 7978821.
9: Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994 Sep 1;58(5):730-5. PubMed PMID: 8077060.
10: Naito K, Nakajima S, Kanbayashi N, Okuyama A, Goto M. Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Agents Actions. 1993 Jul;39(3-4):182-6. PubMed PMID: 8304246.
